Neurocrine Biosciences Inc
NASDAQ: NBIX
$133.23
+$0.24 (+0.2%)
Closing price April 17, 2024
After a wretched 2016, when many of the top biotech companies were hit hard by campaign rhetoric, the industry has roared back to life this year. Here are four big opportunities for aggressive...
Published:
Last Updated:
Many on Wall Street feel that some of the more speculative institutional tech money may be rotating into the biotechs, and with good reason.
Published:
Last Updated:
The equity markets have been putting in a grinding, sideways move since March 1st, and may be getting ready for a jump higher. Analysts at Jefferies have some picks to take advantage of the move...
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls on Friday include Celgene, Continental Resources, Hess, Renewable Energy, U.S. Bancorp and Zynga.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Wednesday include Adobe, HP, Lululemon, Neurocrine Biosciences, Pepsi and Under Armour.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Friday include Alphabet, Caterpillar, Ford, Intel, Microsoft, Weatherford International and Wynn Resorts.
Published:
Last Updated:
A new Jefferies research report makes the case that five top biotech companies may be right in the cross-hairs of the biotech giants or perhaps large pharmaceutical companies.
Published:
Last Updated:
24/7 Wall St. has collected several catalysts for biotech and pharmaceutical companies that are coming up in the first two months of 2017.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Thursday morning include Brocade Communications Systems, Facebook, First Solar, Fitbit, ONEOK Partners and Sunrun.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Tuesday morning include Chipotle Mexican Grill, IBM, Level 3 Communications, Netflix, PayPal and Salesforce.com.
Published:
Last Updated:
Now is the time to look for good growth stocks as the second half of the year could have solid upside after a flat first half.
Published:
Last Updated:
In a recent research report, Jefferies is out with its top growth stock calls to kick off June, and we found three that look very attractive now and that also seem to have outsized upside potential.
Published:
Last Updated:
Here are seven speculative biotech and biohealth players in which analyst calls during the week ending May 27 have given major upside projections.
Published:
Last Updated:
These four solid growth companies are trading well below recent highs and the Jefferies price targets. With very solid upside potential, they look extremely good now.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Monday morning include Alcoa, Boston Scientific, Schlumberger, Sony and Staples.
Published:
Last Updated: